.png){kind=icon}
.png){kind=icon}
Return
Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis
.png){kind=icon}
PRE
AI
DOI：10.1016/S2352-3018(25)00043-8.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
In the REPRIEVE trial of statin therapy in people with HIV, pitavastatin reduced major adverse cardiovascular events (MACE) among those with low-to-moderate risk of cardiovascular disease (CVD). We aimed to investigate associations between former and current use of antiretroviral therapy (ART) on entry into the REPRIEVE trial and the development of MACE.
Keywords:
statin therapy
HIV
cardiovascular disease
antiretroviral therapy
MACE
Journal
IF:
13
Papers:
1.4K
Citations:
6.2K
Organization
View more organizations